Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Respimat inhaler

- PMLiVE

CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021

- PMLiVE

Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy

Project will aim to discover and develop a gene therapy for sickle cell disease

Onyx Health Targets Digital Growth with New Executive Director

Healthcare marketing communications agency Onyx Health have appointed Trevor Pill as their new Executive Director

Onyx Health

- PMLiVE

Rare genetic diseases – what’s in store for 2021?

Why personalised medicine based on our own genomes is the future of healthcare

- PMLiVE

Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients

Tocilizumab, marketed as Actemra/RoActemra, also reduced time spent in hospital in RECOVERY trial

Covid-19: how is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas

Wilmington Healthcare

Roche Basel Switzerland

Roche’s diagnostic business sales offer a bright spot in Q4

Company's pharmaceutical division sales slipped due to biosimilar competition

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

- PMLiVE

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

Agency is due to make a decision for the approval by May 2021

Roche Basel Switzerland

Roche’s flu pill Xofluza gains EU approval

EU approval is based on results from three phase 3 studies

- PMLiVE

Two drugs found to reduce mortality in severe COVID-19 patients

Actemra and Kevzara also improved recovery times among critically ill COVID-19 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links